29 related articles for article (PubMed ID: 38518167)
1. Discovery of a T cell proliferation-associated regulator signature correlates with prognosis risk and immunotherapy response in bladder cancer.
Yan T; Zhou W; Li C
Int Urol Nephrol; 2024 May; ():. PubMed ID: 38789872
[TBL] [Abstract][Full Text] [Related]
2. T cell-mediated tumor killing based signature to predict the prognosis and immunotherapy for glioblastoma.
Liu H; Shi K; Wei Z; Zhang Y; Li J
Heliyon; 2024 May; 10(10):e31207. PubMed ID: 38813229
[TBL] [Abstract][Full Text] [Related]
3. Identification of the CD8+ T-cell Related Signature for Predicting the Prognosis of Gastric Cancer Based on Integrated Analysis of Bulk and Single-cell RNA Sequencing Data.
Zhu ZG; Wang Z; Wu Q; Miao DL; Jin YQ; Chen L
J Immunother; 2024 May; ():. PubMed ID: 38809517
[TBL] [Abstract][Full Text] [Related]
4. Identification and validation of a platelet-related signature for predicting survival and drug sensitivity in multiple myeloma.
Lin Z; Wang Q; Zheng Z; Zhang B; Zhou S; Zheng D; Chen Z; Zheng S; Zhu S; Zhang X; Lan E; Zhang Y; Lin X; Zhuang Q; Qian H; Hu X; Zhuang Y; Jin Z; Jiang S; Ma Y
Front Pharmacol; 2024; 15():1377370. PubMed ID: 38818376
[No Abstract] [Full Text] [Related]
5. Construction of a TAN-associated risk score model with integrated multi-omics data analysis and clinical validation in gastric cancer.
Xu Z; Zhang L; Wang X; Pan B; Zhu M; Wang T; Xu W; Li L; Wei Y; Wu J; Zhou X
Life Sci; 2024 May; 349():122731. PubMed ID: 38782354
[TBL] [Abstract][Full Text] [Related]
6. RAD51 Expression as a Biomarker to Predict Efficacy of Platinum-Based Chemotherapy and PD-L1 Blockade for Muscle-Invasive Bladder Cancer.
Li B; Jin K; Liu Z; Su X; Xu Z; Liu G; Xu J; Chang Y; Wang Y; Zhu Y; Xu L; Wang Z; Liu H; Zhang W
J Immunother; 2024 May; ():. PubMed ID: 38800996
[TBL] [Abstract][Full Text] [Related]
7. Pathomic model based on histopathological features and machine learning to predict IDO1 status and its association with breast cancer prognosis.
Zhuo X; Deng H; Qiu M; Qiu X
Breast Cancer Res Treat; 2024 May; ():. PubMed ID: 38780888
[TBL] [Abstract][Full Text] [Related]
8. Transient receptor potential channels' genes forecast cervical cancer outcomes and illuminate its impact on tumor cells.
Jiang S; Lin X; Wu Q; Zheng J; Cui Z; Cai X; Li Y; Zheng C; Sun Y
Front Genet; 2024; 15():1391842. PubMed ID: 38784033
[No Abstract] [Full Text] [Related]
9. SLC7A5 correlated with malignancies and immunotherapy response in bladder cancer.
Zhang C; Wang Y; Guo X; Wang Z; Xiao J; Liu Z
Cancer Cell Int; 2024 May; 24(1):182. PubMed ID: 38790003
[TBL] [Abstract][Full Text] [Related]
10. Integrative analysis of single-cell and bulk RNA sequencing unveils a machine learning-based pan-cancer major histocompatibility complex-related signature for predicting immunotherapy efficacy.
Feng JL; Liang B; Zheng WJ; Xu L; Zhou QY; Chen J
Cancer Immunol Immunother; 2024 May; 73(7):121. PubMed ID: 38714579
[TBL] [Abstract][Full Text] [Related]
11. TES and SLC40A1 as potential biomarkers for predicting survival in T-cell acute lymphoblastic leukemia.
Zeng X; Liu K; Xu R; Zhang L; Lai P; Du X; Weng J
Acta Haematol; 2024 May; ():. PubMed ID: 38806013
[TBL] [Abstract][Full Text] [Related]
12. Decoding Gastric Cancer: Machine Learning Insights Into the Significance of COMMDs Family in Immunotherapy and Diagnosis.
Wan R; Pan L; Wang Q; Shen G; Guo R; Qin Y; Huang X; Wang R; Fan X
J Cancer; 2024; 15(11):3580-3595. PubMed ID: 38817875
[TBL] [Abstract][Full Text] [Related]
13. Commentary: Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma.
Wu L; Li X; Yan J
Transl Oncol; 2024 Jul; 45():101995. PubMed ID: 38789241
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
Altern Ther Health Med; 2024 Mar; ():. PubMed ID: 38518167
[TBL] [Abstract][Full Text] [Related]
15. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
Dong Y; Wu X; Xu C; Hameed Y; Abdel-Maksoud MA; Almanaa TN; Kotob MH; Al-Qahtani WH; Mahmoud AM; Cho WC; Li C
Aging (Albany NY); 2024 Feb; 16(3):2591-2616. PubMed ID: 38305808
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.
Chen L; Lin J; Wen Y; Chen Y; Chen CB
Front Oncol; 2023; 13():1291720. PubMed ID: 38023241
[TBL] [Abstract][Full Text] [Related]
17. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
18. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
[TBL] [Abstract][Full Text] [Related]
19. Constructing and validating a risk model based on neutrophil-related genes for evaluating prognosis and guiding immunotherapy in colon cancer.
Wang S; Wang L; Qiu M; Lin Z; Qi W; Lv J; Wang Y; Lu Y; Li X; Chen W; Qiu W
J Gene Med; 2024 Apr; 26(4):e3684. PubMed ID: 38618694
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
